EUCTR2018-002901-68-FR招募中1 期
Double-blind, controlled, randomized phase 2 study of efficacy, safety, pharmacokinetics and pharmacodynamics of a daily oral administration of MAP4343 during 6 weeks in antidepressant-non responders patients experiencing a major depressive episode
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- MAPREG
- 入组人数
- 110
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1- Antidepressant drug Resistance level from to 2 to 4 inclusive;
- •2- Patient experiencing a Major Depressive Episod (MDE) according to DSM-V criteria. MDE can be isolated or recurrent. The diagnosis is based on Mini-International Neuropsychiatric Interview (MINI) test;
- •3- Patient should have received a previous antidepressant treatment in monotherapy: IRSS, IRSNA, Tricyclique, IMAO or other drug class prescribed at the maximal dose recommended before the selection;
- •4- Hamilton Depression Rating Scale (HDRS) scores > 21;
- •5- Global clinical Impressions scale (GCI) > 4;
- •6- Male or female patient, aged 18 to 65 years inclusive;
- •7- Females of childbearing potential/Sexually active males with partner of childbearing potential: commitment to consistently and correctly use an acceptable method of birth control (oral, transdermal, systemic or implant contraception birth control, intrauterine devices, diaphragm or condoms) for the duration of the trial and for 4 months after the last study drug administration;
- •Females of non-childbearing potential: either surgically sterilized or at least 1 year postmenopausal (amenorrhoea duration at least 12 months);
- •8- Negative pregnancy test at screening baseline;
- •9- Body Mass Index (BMI) between 18 and 30 kg/m2 inclusive;
- •10- Laboratory parameters within the normal range of the laboratory (hematological, blood chemistry tests, urinalysis, hormonology). Individual values out of the normal range can be accepted if judged clinically non relevant by the Investigator;
- •11- Normal ECG recording on a 12-lead ECG at the screening visit:
- •o 120 < PR < 210 ms,
- •o QRS < 120 ms,
- •o QTcf = 430 ms for male and < 450 ms for female,
- •o No sign of any trouble of sinusal automatism,
- •o Or considered NCs by investigators;
- •12- Normal Blood Pressure (BP) and Heart Rate (HR) at the screening visit after 10 minutes in supine position:
- •o 95 mmHg = Systolic Blood Pressure (SBP) = 140 mmHg,
- •o 50 mmHg = Diastolic Blood Pressure (DBP) = 90 mmHg,
- •o 50 bpm = HR = 80 bpm,
- •o Or considered NCs by investigators;
- •13- Signing a written informed consent prior to selection;
- •14- Covered by Health Insurance System and / or in compliance with the recommendations of National Law in force relating to biomedical research.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 110
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1- MDE with mood congruent or not congruent psychotic characteristics;
- •2- Patient hospitalized following the procedures: Psychiatric care at the request of another person (soins psychiatriques à la demande d’un tiers) or Psychiatric care at the request of the state representative (soins psychiatriques sur décision du représentant de l’Etat);
- •3- suicidal risk in the last month before randomization (MINI 5.00; suicidal risk section or item 3 of HDRS=3);
- •4- History of other psychiatric disorder than DME except global anxiety, social phobia, panic troubles that should be accepted. In particular, patients who experienced a depressive state associated with bipolar disorder 1 or 2, schizophrenic or schizo-affective disorder should not be included;
- •5- Presence or history of protein drug hypersensitivity, or allergic disease diagnosed and treated by a physician;
- •6- Patients who are pregnant or breastfeeding. Patients should not be enrolled if they plan to become pregnant during the time of study participation;
- •7- Any drug intake during the last month prior to the first administration except those defined in Section 5.3;
- •8- General anaesthesia within 3 months before administration;
- •9- Major surgery within 28 days prior to randomization or major surgery planned during the next 6 months;
- •10- Positive HBs antigen or anti HCV antibody, or positive results for HIV 1 or 2 tests;
- •11- Significant renal disease, defined as a history of chronic renal failure requiring dialysis or kidney transplant, calculated creatinine clearance = 60 mL/min;
- •12- Blood donation (including in the frame of a clinical trial) within 2 months before administration;
- •13- Subject who, in the judgment of the Investigator, is likely to be non-compliant or uncooperative during the study, or unable to cooperate because of a language problem, poor mental development;
- •14- Medical history which in the opinion of the investigator would make the patient unsuitable for participation in the study (including, but not limited, to patients with coronary insufficiency, thromboembolism diseases);
- •15- Exclusion period of a previous study;
- •16- No possibility of contact in case of emergency
- •17- History or presence of drug or alcohol abuse (alcohol consumption > 40 grams / day);
- •18- Administrative or legal supervision;
研究者
相似试验
进行中（未招募）
1 期
Clinical trial to evaluate the efficacy and the safety of OSE-127 versus placebo in subjects with ulcerative colitis who have failed or are intolerant to previous treatment(s)Moderate to severe Ulcerative ColitisMedDRA version: 20.1Level: LLTClassification code 10045365Term: Ulcerative colitisSystem Organ Class: 10017947 - Gastrointestinal disordersEUCTR2020-001398-59-BGOSE Immunotherapeutics140
进行中（未招募）
1 期
Clinical trial to evaluate the efficacy and the safety of OSE-127 versus placebo in subjects with ulcerative colitis who have failed or are intolerant to previous treatment(s)Moderate to severe Ulcerative ColitisMedDRA version: 20.1Level: LLTClassification code 10045365Term: Ulcerative colitisSystem Organ Class: 100000004856EUCTR2020-001398-59-LVOSE Immunotherapeutics150
进行中（未招募）
1 期
Clinical trial to evaluate the efficacy and the safety of OSE-127 versus placebo in subjects with ulcerative colitis who have failed or are intolerant to previous treatment(s)Moderate to severe Ulcerative ColitisMedDRA version: 20.1Level: LLTClassification code 10045365Term: Ulcerative colitisSystem Organ Class: 100000004856EUCTR2020-001398-59-HROSE Immunotherapeutics140
进行中（未招募）
1 期
Clinical trial to evaluate the efficacy and the safety of OSE-127 versus placebo in subjects with ulcerative colitis who have failed or are intolerant to previous treatment(s)Moderate to severe Ulcerative ColitisMedDRA version: 20.1Level: LLTClassification code 10045365Term: Ulcerative colitisSystem Organ Class: 100000004856EUCTR2020-001398-59-BEOSE Immunotherapeutics140
招募中
2 期
Phase 2 study of oral semaglutide tablet for patients with Parkinson's diseaseD010300Parkinson's diseaseJPRN-jRCT2051230090Kimura Yasuyoshi99